Development and Preclinical Evaluation of a A-FABP Neutralizing Monoclonal Antibody for Ischemic Stroke Treatment
Grant Data
Project Title
Development and Preclinical Evaluation of a A-FABP Neutralizing Monoclonal Antibody for Ischemic Stroke Treatment
Principal Investigator
Dr Hoo, Ruby Lai Chong
(Project Coordinator (PC))
Co-Investigator(s)
Dr Shu Lingling
(Co-Investigator)
Professor Xu Aimin
(Co-Investigator)
Dr Liao Boya
(Co-Investigator)
Duration
24
Start Date
2019-09-01
Amount
1477458
Conference Title
Development and Preclinical Evaluation of a A-FABP Neutralizing Monoclonal Antibody for Ischemic Stroke Treatment
Presentation Title
Keywords
A-FABP Neutralizing Monoclonal Antibody, Ischemic Stroke Treatment
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
GHP/079/18SZ
Grant Type
Guangdong-Hong Kong Technology Cooperation Funding Scheme
Funding Year
2019
Status
Completed
Objectives
We will develop antibody drugs for ischemic stroke treatment based on the research outcomes of HK RGC projects and the technique platform of Shenzhen collaborator. We have found a novel therapeutic target for safely and effectively treating the ischemic stroke, and hence aim to develop a neutralizing monoclonal antibody with high specificity and high affinity, and evaluate the pharmacokinetics, safety and therapeutic efficacy in animal model. We anticipate to generate a candidate antibody drug for stroke with full intellectual property, and complete the data collection and product optimization required for future commercialization and clinical trials. Given the vast number of stroke patients and rareness of therapies, the market and potential revenue of our drug will be immeasurable.